SCHEMBL10780803

SCHEMBL10780803

CC(C)(C)OC(=O)N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 8/20 0.59
THRA P10827 6/20 0.59
PPARG P37231 6/20 0.59
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
LMNA P02545 4/20 0.59
TTR P02766 2/20 0.59
ADORA3 P0DMS8 2/20 0.59
PDE4D Q08499 2/20 0.59
HSD17B10 Q99714 2/20 0.59
RXRA P19793 2/20 0.59
NR1I2 O75469 2/20 0.59
NR3C1 P04150 1/20 0.59
CYP1A2 P05177 1/20 0.59
HTR1A P08908 1/20 0.59
CYP2C9 P11712 1/20 0.59
TBXA2R P21731 1/20 0.59
NTSR1 P30989 1/20 0.59
HTR2B P41595 1/20 0.59
USP2 O75604 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1526069 1.00 THRB (0.59) THRBTHRAPPARGMEN1KMT2A
SCHEMBL8417806 1.00 THRB (0.59) THRBTHRAPPARGMEN1KMT2A
SCHEMBL18558000 0.96 THRB (0.55) THRBTHRAPPARGMEN1KMT2A
Ethylenediamine SCHEMBL11090366 0.96 THRB (0.57) THRBTHRAPPARGMEN1KMT2A
Putrescine SCHEMBL11092650 0.94 THRB (0.55) THRBTHRAPPARGMEN1KMT2A
SCHEMBL10780866 0.93 THRB (0.57) THRBTHRAPPARGMEN1KMT2A
SCHEMBL12808939 0.91 THRB (0.56) THRBTHRAPPARGMEN1KMT2A
SCHEMBL13952218 0.91 ACE (0.50) THRBTHRAPPARGMEN1KMT2A
SCHEMBL21243772 0.91 ACE (0.58) PPARGITGB3ITGAVACEITGA2B
SCHEMBL5160323 0.91 ACE (0.58) PPARGITGB3ITGAVACEITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-04-30 US disclosed
US-20260049178-A1 CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-02-19 US disclosed
US-20260041799-A1 HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-02-12 US disclosed
US-20260014282-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-01-15 US disclosed
US-20250249130-A1 RADIOPAQUE POLYPEPTIDES FOR INJECTABLE COMPOSITIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-08-07 US disclosed
US-20250059237-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-02-20 US disclosed
EP-0108400-B1 DETERMINATION OF UNSATURATED THYROXINE BINDING PROTEIN SITES USING FLUORESCENCE POLARIZATION TECHNIQUES ABBOTT LABORATORIES (US) 1987-04-29 EP disclosed
US-4476228-A Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques ABBOTT LABORATORIES (US) 1984-10-09 US disclosed
EP-0108400-A2 Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques ABBOTT LABORATORIES (US) 1984-05-16 EP disclosed
EP-0108403-A2 Substituted carboxyfluoresceins ABBOTT LABORATORIES (US) 1984-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059237-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM HDGF, IAPP, QRFPR THRB 862/4885THRA 797/4885PPARG 1495/4885
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS KLK3, BRDT, BPHL THRB 955/4885THRA 358/4885PPARG 734/4885
US-20260049178-A1 CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM NPPA, MACF1, IGF1R THRB 651/4885THRA 39/4885PPARG 2055/4885
US-20260014282-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS IAPP, NPPA, ARG1 THRB 434/4885THRA 330/4885PPARG 1195/4885
US-20260041799-A1 HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME PAM, CRYAA, COL1A1 THRB 2135/4885THRA 562/4885PPARG 4275/4885
US-20250249130-A1 RADIOPAQUE POLYPEPTIDES FOR INJECTABLE COMPOSITIONS IAPP, IGFBP6, NPPA THRB 1550/4885THRA 2016/4885PPARG 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.